Methotrexate hydrate
SIGMA/A6770 - ≥98% (HPLC), powder
Synonym: 4-
CAS Number: 133073-73-1
Empirical Formula (Hill Notation): C20H22N8O5 · xH2O
Molecular Weight: 454.44 (anhydrous basis)
MDL Number: MFCD00150847
Linear Formula: C20H22N8O5 · xH2O
Product Type: Chemical
| assay | ≥98% (HPLC) |
| biological source | synthetic (organic) |
| color | , yellow to very dark yellow to very dark orange |
| form | powder |
| InChI | 1S/C20H22N8O5.H2O/c1-28(9 |
| InChI key | FPJYMUQSRFJSEW-ZOWNYOTGSA |
| mp | 185-204 °C |
| Quality Level | 200 ![]() |
| SMILES string | [H]O[H].CN(Cc1cnc2nc(N)nc |
| solubility | H2O: insoluble |
| storage temp. | −20°C |
| Application: | Potent inhibitor of dihydrofolate reductase and agent for antitumor studies. Use to inhibit dihydrofolate reductase in DHFR-based protein expression systems. |
| Application: | Potent inhibitor of dihydrofolate reductase and agent for antitumor studies. Use to inhibit dihydrofolate reductase in DHFR-based protein expression systems. Also effective in treatment of pyrimethamine-resistant Plasmodium vivax malaria parasites. |
| Application: | Potent inhibitor of dihydrofolate reductase and agent for antitumor studies. Use to inhibit dihydrofolate reductase in DHFR-based protein expression systems. Also shows immunosuppressive effects in, e.g., rheumatoid arthritis. |
| Symbol | ![]() GHS06,GHS08 |
| Signal word | Danger |
| Hazard statements | H301 - H315 - H319 - H360FD |
| Precautionary statements | P201 - P202 - P264 - P301 + P310 - P302 + P352 - P305 + P351 + P338 |
| Hazard Codes | T |
| Risk Statements | 61-25-36/38 |
| Safety Statements | 53-26-36/37-45 |
| RIDADR | UN 1544PSN1 6.1 / PGIII |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥98% (HPLC) |
| mp | 185-204 °C |
| Storage Temp. | −20°C |
| UNSPSC | 12352202 |



